The p53 network in head and neck cancer.
暂无分享,去创建一个
[1] R H Hruban,et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[2] C. Ostwald,et al. p53 mutational spectra are different between squamous‐cell carcinomas of the lip and the oral cavity , 2000, International journal of cancer.
[3] C. Bradford,et al. Predictive factors in head and neck cancer. , 1999, Hematology/oncology clinics of North America.
[4] E. Dellambra,et al. Downregulation of 14-3-3σ Prevents Clonal Evolution and Leads to Immortalization of Primary Human Keratinocytes , 2000, The Journal of cell biology.
[5] K. Mancer,et al. Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma , 2001, Oncogene.
[6] J. Bourhis,et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.
[7] R. Hruban,et al. The incidence of p53 mutations increases with progression of head and neck cancer. , 1993, Cancer research.
[8] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[9] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[10] E. Androphy,et al. AMF1 (GPS2) Modulates p53 Transactivation , 2001, Molecular and Cellular Biology.
[11] G. Sanguineti,et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. , 1992, The New England journal of medicine.
[12] B. Gusterson,et al. Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia , 2002, Oncogene.
[13] W. El-Deiry,et al. Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.
[14] W. El-Deiry,et al. BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets , 2002, Molecular and Cellular Biology.
[15] D. Livingston,et al. Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.
[16] A. Flahault,et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R H Hruban,et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[18] J. Overgaard,et al. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] E. Appella,et al. Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.
[20] Yoichi Taya,et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.
[21] J. Y. Park,et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. , 1998, Carcinogenesis.
[22] T. McDonnell,et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. , 1995, Cancer research.
[23] S. Franceschi,et al. Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aero‐digestive tract , 1995, International journal of cancer.
[24] M. Gentile,et al. Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis , 2001, Oncogene.
[25] W. Foulkes,et al. No association betweenP53codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck , 2000, British Journal of Cancer.
[26] W. Lam,et al. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[27] D. Brachman,et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. , 1992, Cancer research.
[28] Xin Lu,et al. ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.
[29] S. Berger,et al. p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.
[30] D. Spandidos,et al. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. , 1997, Cancer research.
[31] C. Harris,et al. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. , 2000, Mutation research.
[32] Z. Hao,et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy , 1997, Oncogene.
[33] D. Pim,et al. Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.
[34] Hongbing Shen,et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. , 2002, Cancer letters.
[35] Giulia Piaggio,et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.
[36] F. Bosch,et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.
[37] A. Malliri,et al. Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. , 1991, British Journal of Cancer.
[38] Irene M. Leigh,et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.
[39] F. Khuri,et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Schönthal,et al. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1 , 2001, Oncogene.
[41] D. Johnston,et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma , 2000, Oncogene.
[42] K. Sugimachi,et al. p53 polymorphism in human papillomavirus-associated esophageal cancer. , 2000, Cancer research.
[43] F. Apiou,et al. hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] G. Bradley,et al. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas , 2000, The Journal of pathology.
[45] J. Walboomers,et al. p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck , 1997, International journal of cancer.
[46] T. Pandita,et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Reiss,et al. Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. , 1995, Gene.
[48] K. Kinzler,et al. 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .
[49] M. Gulley,et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] P. Laurent-Puig,et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. , 2000, Cancer research.
[51] E. Appella,et al. p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* , 2000, The Journal of Biological Chemistry.
[52] C. R. Leemans,et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. , 2002, The American journal of pathology.
[53] D. Sidransky,et al. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. , 1999, Human pathology.
[54] A. Kropveld,et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[55] S. Goodman,et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.
[56] B. Gusterson,et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. , 2002, Cancer research.
[57] G. Snow,et al. p53 immunoexpression in non‐malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management , 2000, The Journal of pathology.
[58] Wei Gu,et al. Synergistic activation of transcription by CBP and p53 , 1997, Nature.
[59] L. Turek,et al. p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[60] F. Khuri,et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.
[61] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[62] T. Soussi,et al. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients , 2000, The Journal of pathology.
[63] G. Snow,et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma , 1998, The Journal of pathology.
[64] Å. Borg,et al. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. , 1998, British Journal of Cancer.
[65] V. Rotter,et al. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.
[66] P. Beaune,et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] I. Tannock,et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.
[68] O. Gallo,et al. Cumulative prognostic value of p53 mutations and bcl‐2 protein expression in head‐and‐neck cancer treated by radiotherapy , 1999, International journal of cancer.
[69] R. Iggo,et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. , 2001, Carcinogenesis.
[70] P. Hainaut,et al. TP53 mutations and MDM2 gene amplification in squamous‐cell carcinomas of the esophagus in South Thailand , 2000, International journal of cancer.
[71] D. Sidransky,et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.
[72] M. Gulley,et al. Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .
[73] I. Ganly,et al. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy , 2000, British Journal of Cancer.
[74] S. Riethdorf,et al. P53-mutation in smears of oral squamous cell carcinoma. , 2000, Anticancer research.
[75] K. Cullen,et al. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging , 2000, Current opinion in oncology.
[76] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[77] R. Ralhan,et al. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. , 1999, Oral oncology.
[78] G. Casey,et al. Frequent p53 mutations in head and neck cancer. , 1992, Cancer research.
[79] J. Langdon,et al. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] T. Wendt,et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] E. Vokes,et al. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. , 2000, Seminars in oncology.
[82] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[83] S. Lippman,et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[85] M. Tang,et al. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers , 1998, Oncogene.
[86] Francesca Storici,et al. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.